Literature DB >> 2210942

Drug resistance in Giardia intestinalis.

J A Upcroft1, P Upcroft, P F Boreham.   

Abstract

Evidence for drug resistance in giardiasis is reviewed and biochemical studies undertaken to determine the basis for this resistance are discussed. Metronidazole and furazolidone, which produce toxic radicals within the cell, have different biochemical mechanisms of action. Resistance to metronidazole is negatively correlated with the intracellular concentration of pyruvateferredoxin oxidoreductase leading to a concomitant decrease in the uptake of free metronidazole into the cell, while resistance to furazolidone appears to be due to an increase in thiol cycling enzymes. At the molecular level resistance to metronidazole is associated with DNA changes. DNA probes which hybridize with specific chromosomes and repetitive sequences indicate that rearrangements both at the chromosome and repetitive DNA level occurred concurrently with the development of metronidazole resistance. The problems of cross-resistance and treatment failures that occur in the absence of resistance are additional difficulties which have important implications for the management of individual patients. New drugs such as azithromycin, while showing great variation in activity against different stocks may be useful in treating some refractory cases of giardiasis. In the community, it is important to recognize the occurrence and spread of drug resistant Giardia, and markers, such as DNA probes, provide methods to monitor potential epidemics and the spread of drug resistant Giardia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210942     DOI: 10.1016/0020-7519(90)90196-t

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  15 in total

1.  High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements.

Authors:  Catherine Z Chen; Liudmila Kulakova; Noel Southall; Juan J Marugan; Andrey Galkin; Christopher P Austin; Osnat Herzberg; Wei Zheng
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  In vivo efficacy of albendazole against Giardia duodenalis in mice.

Authors:  J A Reynoldson; R C Thompson; B P Meloni
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

3.  The course of experimental giardiasis in Mongolian gerbil.

Authors:  Radka Pecková; Bohumil Sak; Dana Květoňová; Martin Kváč; Eva Koriťáková; Ivona Foitová
Journal:  Parasitol Res       Date:  2018-05-24       Impact factor: 2.289

Review 4.  Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.

Authors:  Wim G J Hol
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-04-16       Impact factor: 1.056

Review 5.  Treatment of giardiasis.

Authors:  T B Gardner; D R Hill
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

6.  Disruption of antigenic variation is crucial for effective parasite vaccine.

Authors:  Fernando D Rivero; Alicia Saura; Cesar G Prucca; Pedro G Carranza; Alessandro Torri; Hugo D Lujan
Journal:  Nat Med       Date:  2010-04-25       Impact factor: 53.440

Review 7.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

Review 8.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

9.  The old and new therapeutic approaches to the treatment of giardiasis: where are we?

Authors:  Haendel G N O Busatti; Joseph F G Santos; Maria A Gomes
Journal:  Biologics       Date:  2009-07-13

10.  A homogenous luminescence assay reveals novel inhibitors for giardia lamblia carbamate kinase.

Authors:  Catherine Z Chen; Noel Southall; Andrey Galkin; Kap Lim; Juan J Marugan; Liudmila Kulakova; Paul Shinn; Danielle van Leer; Wei Zheng; Osnat Herzberg
Journal:  Curr Chem Genomics       Date:  2012-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.